{"id":35406,"date":"2025-06-17T17:57:23","date_gmt":"2025-06-17T09:57:23","guid":{"rendered":"https:\/\/flcube.com\/?p=35406"},"modified":"2025-06-17T17:57:24","modified_gmt":"2025-06-17T09:57:24","slug":"fosun-pharma-collaborates-with-teva-on-development-of-tev-56278-in-china-and-southeast-asia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35406","title":{"rendered":"Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China&#8217;s Shanghai Fosun Pharmaceutical (Group) Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>) and Israel-based Teva Pharmaceutical Industries Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/TEVA:NYSE\">NYSE: TEVA<\/a>) announced this week a strategic collaboration for the development of investigational drug TEV-56278. Under the agreement, Fosun Pharma secures exclusive rights to develop, manufacture, and commercialize TEV-56278 in China (including Hong Kong, Macau, and Taiwan) and certain Southeast Asian countries, with the goal of accelerating clinical data development. Teva retains the rights to the drug in all other global markets. No financial details were disclosed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>TEV-56278 and Technology<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">TEV-56278 is an anti-PD1-IL2 fusion protein developed using Teva&#8217;s proprietary ATTENUKINE technology. This innovative approach enables selective delivery of IL-2 to PD-1-positive T cells, enhancing T cell anti-tumor activity while minimizing off-target systemic toxicity.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Clinical and Efficacy Profile<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The candidate molecule demonstrates potential for high efficacy with reduced toxicity across multiple immuno-oncology indications. Currently in Phase I clinical trials, TEV-56278 is being evaluated for various cancer types, including melanoma.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Israel-based Teva Pharmaceutical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":35407,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[159,893,107,18,892,1071],"class_list":["post-35406","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-fosun-pharmaceutical","tag-hkg-2196","tag-immunotherapy","tag-pd-1-l1","tag-sha-600196","tag-teva-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced this week a strategic collaboration for the development of investigational drug TEV-56278. Under the agreement, Fosun Pharma secures exclusive rights to develop, manufacture, and commercialize TEV-56278 in China (including Hong Kong, Macau, and Taiwan) and certain Southeast Asian countries, with the goal of accelerating clinical data development. Teva retains the rights to the drug in all other global markets. No financial details were disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35406\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia\" \/>\n<meta property=\"og:description\" content=\"China&#039;s Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced this week a strategic collaboration for the development of investigational drug TEV-56278. Under the agreement, Fosun Pharma secures exclusive rights to develop, manufacture, and commercialize TEV-56278 in China (including Hong Kong, Macau, and Taiwan) and certain Southeast Asian countries, with the goal of accelerating clinical data development. Teva retains the rights to the drug in all other global markets. No financial details were disclosed.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35406\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-17T09:57:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-17T09:57:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1713-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35406#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35406\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia\",\"datePublished\":\"2025-06-17T09:57:23+00:00\",\"dateModified\":\"2025-06-17T09:57:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35406\"},\"wordCount\":176,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35406#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1713-1.webp\",\"keywords\":[\"Fosun Pharmaceutical\",\"HKG: 2196\",\"Immunotherapy\",\"PD-1\\\/L1\",\"SHA: 600196\",\"Teva Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35406#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35406\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35406\",\"name\":\"Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35406#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35406#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1713-1.webp\",\"datePublished\":\"2025-06-17T09:57:23+00:00\",\"dateModified\":\"2025-06-17T09:57:24+00:00\",\"description\":\"China's Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced this week a strategic collaboration for the development of investigational drug TEV-56278. Under the agreement, Fosun Pharma secures exclusive rights to develop, manufacture, and commercialize TEV-56278 in China (including Hong Kong, Macau, and Taiwan) and certain Southeast Asian countries, with the goal of accelerating clinical data development. Teva retains the rights to the drug in all other global markets. No financial details were disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35406#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35406\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35406#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1713-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1713-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35406#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia - Insight, China&#039;s Pharmaceutical Industry","description":"China's Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced this week a strategic collaboration for the development of investigational drug TEV-56278. Under the agreement, Fosun Pharma secures exclusive rights to develop, manufacture, and commercialize TEV-56278 in China (including Hong Kong, Macau, and Taiwan) and certain Southeast Asian countries, with the goal of accelerating clinical data development. Teva retains the rights to the drug in all other global markets. No financial details were disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35406","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia","og_description":"China's Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced this week a strategic collaboration for the development of investigational drug TEV-56278. Under the agreement, Fosun Pharma secures exclusive rights to develop, manufacture, and commercialize TEV-56278 in China (including Hong Kong, Macau, and Taiwan) and certain Southeast Asian countries, with the goal of accelerating clinical data development. Teva retains the rights to the drug in all other global markets. No financial details were disclosed.","og_url":"https:\/\/flcube.com\/?p=35406","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-17T09:57:23+00:00","article_modified_time":"2025-06-17T09:57:24+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1713-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35406#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35406"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia","datePublished":"2025-06-17T09:57:23+00:00","dateModified":"2025-06-17T09:57:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35406"},"wordCount":176,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35406#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1713-1.webp","keywords":["Fosun Pharmaceutical","HKG: 2196","Immunotherapy","PD-1\/L1","SHA: 600196","Teva Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35406#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35406","url":"https:\/\/flcube.com\/?p=35406","name":"Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35406#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35406#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1713-1.webp","datePublished":"2025-06-17T09:57:23+00:00","dateModified":"2025-06-17T09:57:24+00:00","description":"China's Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced this week a strategic collaboration for the development of investigational drug TEV-56278. Under the agreement, Fosun Pharma secures exclusive rights to develop, manufacture, and commercialize TEV-56278 in China (including Hong Kong, Macau, and Taiwan) and certain Southeast Asian countries, with the goal of accelerating clinical data development. Teva retains the rights to the drug in all other global markets. No financial details were disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35406#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35406"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35406#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1713-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1713-1.webp","width":1080,"height":608,"caption":"Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35406#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1713-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35406"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35406\/revisions"}],"predecessor-version":[{"id":35408,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35406\/revisions\/35408"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35407"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}